Business Wire
HeathWarehouse.com to Register With the Securities and Exchange Commission
Tuesday, 16 January 2018 02:06
Read more...
 
HeathWarehouse.com to Register With the Securities and Exchange Commission
Tuesday, 16 January 2018 02:06
Read more...
 
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
Tuesday, 16 January 2018 02:06
Phase 2 Trial will investigate Levosimendan in Pulmonary Hypertension-WHO Group 2 patients with preserved ejection fraction (PH-HFpEF)
Read more...
 
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
Tuesday, 16 January 2018 02:06
Phase 2 Trial will investigate Levosimendan in Pulmonary Hypertension-WHO Group 2 patients with preserved ejection fraction (PH-HFpEF)
Read more...
 
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
Tuesday, 16 January 2018 02:06
Read more...
 
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
Tuesday, 16 January 2018 02:06
Read more...
 
Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint Inhibitors
Tuesday, 16 January 2018 02:06
Trial to evaluate the potential for the company’s most advanced small-molecule EZH2 inhibitor to be used in combination with Yervoy® and other immunotherapies
Read more...
 
Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint Inhibitors
Tuesday, 16 January 2018 02:06
Trial to evaluate the potential for the company’s most advanced small-molecule EZH2 inhibitor to be used in combination with Yervoy® and other immunotherapies
Read more...
 
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
Tuesday, 16 January 2018 02:06
- Zimura Is Also Being Investigated in Ongoing Clinical Trials for the Treatment of Dry and Wet Age-related Macular Degeneration (AMD) and Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) -
Read more...
 
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
Tuesday, 16 January 2018 02:06
- Zimura Is Also Being Investigated in Ongoing Clinical Trials for the Treatment of Dry and Wet Age-related Macular Degeneration (AMD) and Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) -
Read more...
 
More Articles...
Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
  • Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
  • << Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

    Page 12 of 5168
    BMR:1